search
Back to results

Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes

Primary Purpose

Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia, Hypoglycemia

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Stepped hyperinsulinaemic-hypoglycaemic clamp study
Insulin pump
Continuous glucose monitor
Low carbohydrate diet
Blinded continuous glucose monitor
Stable isotope studies- D2 Glucose and D5 Glycerol
Sponsored by
University of Edinburgh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Type 1 Diabetes focused on measuring Type 1 diabetes, Hypoglycaemia, Hypoglycemia, Glucagon, Insulin, Low carbohydrate diet, Stable isotope

Eligibility Criteria

21 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participants with Type 1 diabetes with C-peptide levels less than 200pmol/L.
  • Type 1 diabetes for 5 years or more.
  • HbA1c greater than or equal to 53 mol/mol.
  • Normal renal function.
  • Normal thyroid function.
  • Gold Score 4-7 (indicating impaired awareness of hypoglycaemia)
  • Willingness to monitor blood ketones daily.
  • Use of freestyle libre device is permitted at study entry and may be continued in participants in group 1

Exclusion Criteria:

  • Current use of a non-approved closed loop / AID system or those on a predictive low glucose suspend insulin pump.
  • Proliferative retinopathy
  • Regular use of real time CGM in the preceding 3 months.
  • History of Diabetic ketoacidosis in the preceding 6 months.
  • Severe hypoglycaemic episode requiring external assistance in the preceding 6 months.
  • Inability to safely use technology used in this study (e.g. impaired vision, memory or dexterity that prevents safe operation of CGM or insulin pump.)
  • Inability to support the technology requirements for the study (e.g. unable to upload study device at home)
  • History of Haemophilia, Cystic Fibrosis, pancreatic disease or complete pancreatectomy, ischaemic heart disease, epilepsy or hypoglycaemia induced seizure
  • History of severe reaction or allergy to adhesive necessary to this study.
  • Unable to adhere to study timetable.
  • Unable to give informed consent.
  • Pregnancy. We will perform a pregnancy test on all eligible participants at baseline.
  • Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas. These may lower insulin requirements and predispose to diabetic ketoacidosis.
  • Concurrent use of medication that may affect blood glucose such as SSRIs
  • A condition, which in the opinion of the investigator, would put the patient or study at risk
  • HbA1c greater than or equal to 75 mmol/mol

Sites / Locations

  • Edinburgh Royal Infirmary/University of EdinburghRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Group 1 - Standard Care

Group 2- Automated insulin delivery and low carbohydrate diet

Arm Description

This group will continue on their standard diabetes care. They will be required to undergo three periods of blinded continuous glucose monitoring each lasting 20-days at: baseline, 4 months and 8 months. Participants in this group will undergo a hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.

This group will be placed on an automated insulin delivery system: Tandem t:slim x2 insulin pump with Control IQ technology and Dexcom G6 continuous glucose monitor. They will also be asked to follow a low-carbohydrate diet of 30-40g of carbohydrate per main meal. At baseline they will have a 20-day period of blinded continuous glucose monitoring. Participants in this group will undergo a stepped hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.

Outcomes

Primary Outcome Measures

The change in plasma glucagon levels (pmol/L) measured during normoglycaemic and hypoglycaemia
Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end

Secondary Outcome Measures

Time in glycaemic range (3.9-10mmol/L)
Percentage time spent in target glycaemic range.
Time spent below the target glycaemic range (<3.9mmol/L)
Percentage of time spent below the target glycaemic range
Time spent above the target glycaemic range (>10mmol/L)
Percentage of time spent above the target glycaemic range
The change in plasma cortisol (nmol/L) levels measured during normoglycaemic and hypoglycaemia
Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end
The change in plasma adrenaline (nmol/L) levels measured during normoglycaemic and hypoglycaemia
Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end
The change in plasma noradrenaline (nmol/L) levels measured during normoglycaemic and hypoglycaemia
Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end
Endogenous glucose production
Measured with stable isotope studies using D2 glucose and D5 glycerol
HbA1c
Difference between baseline and study end
Change in quality of life at trial entry and end.
Measured using the EQ5D-5L- a quality of life questionnaire comprising of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension consists of five levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant ticks the box most relevant to them at the time of taking the questionnaire. This response is converted into a 1 digit number and the 5 numbers from a domain can be combined to describe the participant's health state. This questionnaire will be completed at trial entry and then at trial end.
Change in emotional distress related to diabetes at trial entry and end.
Diabetes Distress Scale (DDS-1)- a 28-item self-reporting scale. Each item can be scored from 1 (not a problem) to 6 (a very serious problem). This questionnaire will be completed at study entry and study end.
Attitude to diabetes technologies
Measured using the Diabetes Technology Questionnaire- a 30 item questionnaire. The participant ranks each item from Very Much (1) to Not at all (5). Participants will complete this questionnaire at study entry and study end. Also assessed using the Diabetes Technology Attitudes Survey- a 5 item questionnaire. The participant ranks each item from Strongly Disagree (1) to Strongly Agree (5).
Change in fear of hypoglycaemic
Measured using the Hypoglycaemia Fear Survey (HFS)- this survey consists of two subscales- Behaviour and Worry. There are 28 items in the survey that the participant ranks from Never (0) to Almost Always (4). Participants will complete this questionnaire at study entry and study end.
Change in confidence of managing hypoglycaemia
Measured using the Hypoglycaemic Confidence Scale- this is a 9 item scale. The participant rates each item from Not Confident at All to Very Confident. Participants will complete this questionnaire at study entry and study end.
Hypoglycaemia awareness
Measured during each clamp study using the Edinburgh Hypoglycaemic Scale- this is a 17 item scale of symptoms of hypoglycaemia. The participant ranks on a scale from Not at all (1) to A Great Deal (7) whether they are experiencing each symptom at the time of the questionnaire being completed.
Trial Making Test
Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end.
Digit Span Test
Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end.
Digit Symbol Substitution Test
Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end.
Four Choice Reaction Time Test
Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end.

Full Information

First Posted
October 7, 2020
Last Updated
January 13, 2022
Sponsor
University of Edinburgh
Collaborators
NHS Lothian, The Leona M. and Harry B. Helmsley Charitable Trust, Tandem Diabetes Care, Inc., DexCom, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04614168
Brief Title
Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes
Official Title
Can Maximising Time in Range Using Automated Insulin Delivery and a Low Carbohydrate Diet Restore the Glucagon Response to Hypoglycaemic in Type 1 Diabetes?
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 26, 2021 (Actual)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
March 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Edinburgh
Collaborators
NHS Lothian, The Leona M. and Harry B. Helmsley Charitable Trust, Tandem Diabetes Care, Inc., DexCom, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Almost all people who have had type 1 diabetes for 5 years have a defect in secretion of the hormone Glucagon. This hormone is involved in the body's response to low blood glucose (hypoglycaemia). It works by releasing glucose stores from the liver to bring the blood glucose back to normal. This defect therefore increases the risk of severe hypoglycaemia. The reason for this Glucagon defect in people with Type 1 diabetes is currently unknown. This study aims to look at the Glucagon response to hypoglycaemia in 24 people with type 1 diabetes to ascertain whether tight blood glucose control over a period of time improves this response. The investigators aim to achieve good blood glucose control using new generation Automated Insulin Delivery systems (AIDs). This system is made of: an insulin pump, a continuous glucose monitor (CGM) and an algorithm that allows adjustment of insulin delivery based on the blood glucose readings from the CGM. This is the most up to date technology that there is in the management of type 1 diabetes. However, people using this technology often still have problems with high blood glucose after eating. To ensure a very good blood glucose control participants will also follow a low carbohydrate diet to prevent this blood glucose rise after meals. The Glucagon response to low blood glucose will be measured at zero and eight months using the hyperinsulinaemic hypoglycaemic clamp technique.
Detailed Description
This is a feasibility pilot study involving 24 participants with type 1 diabetes. Participants will be recruited from the local type 1 diabetes clinic and insulin pump waiting list. Each participant will enter the trial for a period of 8 months. The investigators aim to test if maximising time in glycaemic range (blood glucose 3.9-10 mmol/L) will restore the glucagon response to insulin-induced hypoglycaemia. After signing informed consent participants will be screened for eligibility against the inclusion and exclusion criteria. Those who are eligible will have an initial 20-day period of baseline blood glucose data collection. This will be achieved using a blinded continuous glucose monitoring (CGM) device. Participants will continue on their pre-trial diabetes care during this period and will be required to monitor their own blood glucose as normal. The participants will be split into two groups using stratified sampling to match for: age, gender and BMI. Group 1 will be the control group. Participants in this group will continue on standard diabetes care for the duration of the trial. Participants will be required to undertake two further periods of blinded CGM monitoring at 4 and 8 months. Group 2 will be the intervention group. Participants in this group will be placed on the automated insulin delivery (AID) system and asked to follow a low carbohydrate diet of 30-40g of carbohydrate per main meal portion. The AID system will consist of: a Tandem t:slim X2 insulin pump with control IQ technology and a Dexcom G6 continuous glucose monitor. After receiving training on the use of the devices these participants will enter a 2 week study run-in period to become accustomed to the devices and so that device settings can be optimised. As a safety measure these participants will be asked to measure blood ketones at least once daily throughout the trial. Study staff will monitor the data from the participants study devices throughout the trial and adjust settings as required to maximise time in glycaemic range. At the beginning and end of the trial all participants will undergo a hyperinsulinaemic hypoglycaemic clamp study to measure their counterregulatory hormone response to hypoglycaemic. Participants will also undergo cognitive tests and assessment of hypoglycaemic awareness during each clamp study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia, Hypoglycemia, Hypoglycemia Unawareness, Glucagon Deficiency, Insulin Hypoglycemia
Keywords
Type 1 diabetes, Hypoglycaemia, Hypoglycemia, Glucagon, Insulin, Low carbohydrate diet, Stable isotope

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be divided into two groups using stratified sampling to match for age, sex and BMI.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1 - Standard Care
Arm Type
Active Comparator
Arm Description
This group will continue on their standard diabetes care. They will be required to undergo three periods of blinded continuous glucose monitoring each lasting 20-days at: baseline, 4 months and 8 months. Participants in this group will undergo a hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
Arm Title
Group 2- Automated insulin delivery and low carbohydrate diet
Arm Type
Experimental
Arm Description
This group will be placed on an automated insulin delivery system: Tandem t:slim x2 insulin pump with Control IQ technology and Dexcom G6 continuous glucose monitor. They will also be asked to follow a low-carbohydrate diet of 30-40g of carbohydrate per main meal. At baseline they will have a 20-day period of blinded continuous glucose monitoring. Participants in this group will undergo a stepped hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
Intervention Type
Procedure
Intervention Name(s)
Stepped hyperinsulinaemic-hypoglycaemic clamp study
Intervention Description
Participants will commence on a primed insulin infusion at a constant rate of 60mU/m2/min along with a variable rate 20% glucose infusion. Participants will have their blood glucose monitored every 5 minutes. The glucose infusion will be altered to achieve the desired blood glucose plateaus of: 5mmol/l, 3mmol/l and 2.5mmol/l. Each plateau will be held for 40 minutes. During each plateau blood samples will be taken on three occasions for: glucagon, cortisol, adrenaline, noradrenaline, D2 glucose and D5 glycerol. On two occasions during each plateau participants will complete the Edinburgh hypoglycaemia scale and the following cognitive tests: trail making test, digit span test, digit symbol substitution test and four choice reaction time test. At the end of the clamp study the insulin infusion will be discontinued and the blood glucose will be allowed to rise to the normal range. Participants will consume lunch before leaving the clinical research facility.
Intervention Type
Device
Intervention Name(s)
Insulin pump
Other Intervention Name(s)
Tandem t:slim x2 with Control IQ technology
Intervention Description
Insulin pump with a built-in algorithm that allows it to work with a CGM device to adjust insulin delivery based on CGM readings.
Intervention Type
Device
Intervention Name(s)
Continuous glucose monitor
Other Intervention Name(s)
Dexcom G6
Intervention Description
Continuous glucose monitoring device that sends data to the insulin pump to allow the algorithm to adjust insulin delivery. Participants are able to see the glucose data from the device when it is used in open mode.
Intervention Type
Other
Intervention Name(s)
Low carbohydrate diet
Intervention Description
30-40g of carbohydrate per main meal portion.
Intervention Type
Device
Intervention Name(s)
Blinded continuous glucose monitor
Other Intervention Name(s)
Dexcom G6
Intervention Description
Allows data on blood glucose to be collected without values altering the behaviour of the participant. Participants have to continue to monitor their own blood glucose while wearing the device in the blinded mode.
Intervention Type
Procedure
Intervention Name(s)
Stable isotope studies- D2 Glucose and D5 Glycerol
Intervention Description
These studies will take place at the same time as the hyperinsulinaemic hypoglycaemic clamp studies. Participants will receive a priming dose of each stable isotope followed by a continuous infusion for the remainder of the clamp study.
Primary Outcome Measure Information:
Title
The change in plasma glucagon levels (pmol/L) measured during normoglycaemic and hypoglycaemia
Description
Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end
Time Frame
8 months
Secondary Outcome Measure Information:
Title
Time in glycaemic range (3.9-10mmol/L)
Description
Percentage time spent in target glycaemic range.
Time Frame
8 months
Title
Time spent below the target glycaemic range (<3.9mmol/L)
Description
Percentage of time spent below the target glycaemic range
Time Frame
8 months
Title
Time spent above the target glycaemic range (>10mmol/L)
Description
Percentage of time spent above the target glycaemic range
Time Frame
8 months
Title
The change in plasma cortisol (nmol/L) levels measured during normoglycaemic and hypoglycaemia
Description
Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end
Time Frame
8 months
Title
The change in plasma adrenaline (nmol/L) levels measured during normoglycaemic and hypoglycaemia
Description
Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end
Time Frame
8 months
Title
The change in plasma noradrenaline (nmol/L) levels measured during normoglycaemic and hypoglycaemia
Description
Measured at baseline and each glucose plateau in a stepped hyperinsulinaemic hypoglycaemic clamp study at study start and study end
Time Frame
8 months
Title
Endogenous glucose production
Description
Measured with stable isotope studies using D2 glucose and D5 glycerol
Time Frame
8 months
Title
HbA1c
Description
Difference between baseline and study end
Time Frame
8 months
Title
Change in quality of life at trial entry and end.
Description
Measured using the EQ5D-5L- a quality of life questionnaire comprising of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension consists of five levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant ticks the box most relevant to them at the time of taking the questionnaire. This response is converted into a 1 digit number and the 5 numbers from a domain can be combined to describe the participant's health state. This questionnaire will be completed at trial entry and then at trial end.
Time Frame
8 months
Title
Change in emotional distress related to diabetes at trial entry and end.
Description
Diabetes Distress Scale (DDS-1)- a 28-item self-reporting scale. Each item can be scored from 1 (not a problem) to 6 (a very serious problem). This questionnaire will be completed at study entry and study end.
Time Frame
8 months
Title
Attitude to diabetes technologies
Description
Measured using the Diabetes Technology Questionnaire- a 30 item questionnaire. The participant ranks each item from Very Much (1) to Not at all (5). Participants will complete this questionnaire at study entry and study end. Also assessed using the Diabetes Technology Attitudes Survey- a 5 item questionnaire. The participant ranks each item from Strongly Disagree (1) to Strongly Agree (5).
Time Frame
8 months
Title
Change in fear of hypoglycaemic
Description
Measured using the Hypoglycaemia Fear Survey (HFS)- this survey consists of two subscales- Behaviour and Worry. There are 28 items in the survey that the participant ranks from Never (0) to Almost Always (4). Participants will complete this questionnaire at study entry and study end.
Time Frame
8 months
Title
Change in confidence of managing hypoglycaemia
Description
Measured using the Hypoglycaemic Confidence Scale- this is a 9 item scale. The participant rates each item from Not Confident at All to Very Confident. Participants will complete this questionnaire at study entry and study end.
Time Frame
8 months
Title
Hypoglycaemia awareness
Description
Measured during each clamp study using the Edinburgh Hypoglycaemic Scale- this is a 17 item scale of symptoms of hypoglycaemia. The participant ranks on a scale from Not at all (1) to A Great Deal (7) whether they are experiencing each symptom at the time of the questionnaire being completed.
Time Frame
8 months
Title
Trial Making Test
Description
Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end.
Time Frame
8 months
Title
Digit Span Test
Description
Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end.
Time Frame
8 months
Title
Digit Symbol Substitution Test
Description
Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end.
Time Frame
8 months
Title
Four Choice Reaction Time Test
Description
Measured during each plateau in a stepped hypoglycaemic clamp study at study entry and study end. Difference in score between plateaus and at trial entry and end.
Time Frame
8 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants with Type 1 diabetes with C-peptide levels less than 200pmol/L. Type 1 diabetes for 5 years or more. HbA1c greater than or equal to 53 mol/mol. Normal renal function. Normal thyroid function. Gold Score 4-7 (indicating impaired awareness of hypoglycaemia) Willingness to monitor blood ketones daily. Use of freestyle libre device is permitted at study entry and may be continued in participants in group 1 Exclusion Criteria: Current use of a non-approved closed loop / AID system or those on a predictive low glucose suspend insulin pump. Proliferative retinopathy Regular use of real time CGM in the preceding 3 months. History of Diabetic ketoacidosis in the preceding 6 months. Severe hypoglycaemic episode requiring external assistance in the preceding 6 months. Inability to safely use technology used in this study (e.g. impaired vision, memory or dexterity that prevents safe operation of CGM or insulin pump.) Inability to support the technology requirements for the study (e.g. unable to upload study device at home) History of Haemophilia, Cystic Fibrosis, pancreatic disease or complete pancreatectomy, ischaemic heart disease, epilepsy or hypoglycaemia induced seizure History of severe reaction or allergy to adhesive necessary to this study. Unable to adhere to study timetable. Unable to give informed consent. Pregnancy. We will perform a pregnancy test on all eligible participants at baseline. Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas. These may lower insulin requirements and predispose to diabetic ketoacidosis. Concurrent use of medication that may affect blood glucose such as SSRIs A condition, which in the opinion of the investigator, would put the patient or study at risk HbA1c greater than or equal to 75 mmol/mol
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shareen Forbes, MBChB, PhD
Phone
+ 44 (0)131 2426741
Email
shareen.forbes@ed.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Faye Baxter, MBChB
Email
fbaxter@ed.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shareen Forbes, MBChB, PhD
Organizational Affiliation
University of Edinburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
Edinburgh Royal Infirmary/University of Edinburgh
City
Edinburgh
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shareen Forbes, MBChB, PhD
Email
shareen.forbes@ed.ac.uk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes

We'll reach out to this number within 24 hrs